NGeneBio

주식회사 엔젠바이오 · KOSDAQ · 354200 · Industry: Other professional, scientific and technical services n.e.c.

Key metrics

Earnings

Revenue, Q3 2026₩13.4bn As of Sep 30, 2026 Source 1 ↗
Revenue QoQ+7.9% As of Sep 30, 2026 Source 1 ↗, Source 2 ↗
Revenue YoY+147.5% As of Sep 30, 2026 Source 1 ↗, Source 2 ↗
Operating income, Q3 2026-₩1.3bn As of Sep 30, 2026 Source 1 ↗
Operating income QoQ-10.5% As of Sep 30, 2026 Source 1 ↗, Source 2 ↗
Operating income YoY+20.5% As of Sep 30, 2026 Source 1 ↗, Source 2 ↗

Share buybacks

Buyback decided, last 3 months₩0 As of Nov 19, 2026
Buyback decided, last 3 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Shares acquired, last 3 months₩0 As of Nov 19, 2026
Shares acquired, last 3 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Treasury shares cancelled, last 3 months₩0 As of Nov 19, 2026
Treasury shares cancelled (number), last 3 months0 shares As of Nov 19, 2026
Treasury shares cancelled, last 3 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Buyback decided, last 12 months₩0 As of Nov 19, 2026
Buyback decided, last 12 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Shares acquired, last 12 months₩0 As of Nov 19, 2026
Shares acquired, last 12 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Treasury shares cancelled, last 12 months₩0 As of Nov 19, 2026
Treasury shares cancelled (number), last 12 months0 shares As of Nov 19, 2026
Treasury shares cancelled, last 12 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗

Potential dilution

CB/BW/EB issued, last 12 months₩0 As of Nov 19, 2026
Rights offering new shares, last 12 months15,150,000 shares As of Nov 10, 2026 Source 1 ↗, Source 2, Source 3
Potential new shares, last 12 months15,150,000 shares As of Nov 10, 2026 Source 1 ↗, Source 2, Source 3
Potential new shares, % of shares94.2% As of Nov 10, 2026 Source 1 ↗, Source 2, Source 3, Source 4 ↗
Conversion price adjustments, last 12 months0 As of Nov 19, 2026

Supply contracts

Supply contracts, last 12 months₩0 As of Nov 19, 2026
Supply contracts vs prior-year revenue0.0% As of Nov 19, 2026
Contracts without a KRW amount0 contracts without a KRW amount excluded As of Nov 19, 2026

Disclosure activity

DART filings, last 3 months24 As of Nov 19, 2026
DART filings, previous 3 months28 As of Nov 19, 2026

Insider transactions

Open-market buys, last 12 months (shares)42,710 shares As of Jul 29, 2026 Source 1 ↗
Open-market buys, last 12 months (amount)₩100m As of Jul 29, 2026 Source 1 ↗
Open-market sells, last 12 months (shares)0 shares As of Nov 19, 2026
Open-market sells, last 12 months (amount)₩0 As of Nov 19, 2026
Net open-market buying, last 12 months (shares)42,710 shares As of Jul 29, 2026 Source 1 ↗
Insiders who bought, last 12 months1 As of Jul 29, 2026 Source 1 ↗

Insider transactions (last 12 months)

Open-market buys: 42,710 shares (₩100m). Open-market sells: 0 shares (₩0). Net open-market buying: +42,710 shares. Insiders who bought: 1.

Trade dateInsider (role)TypeSharesPriceAmount
Aug 14, 2026Eseueichihelseukeeotuja1hojohap (Controlling shareholder)Other (OTC sell)-785,559 shares——
Aug 4, 2026Eseueichihelseukeeotuja1hojohap (Controlling shareholder)Other (Other increase)+1,571,118 shares₩1,074₩1.7bn
Jul 29, 2026Kim Min-sik (Registered director)Open-market buy+30,208 shares₩2,380₩72m
Jul 28, 2026Kim Min-sik (Registered director)Open-market buy+12,502 shares₩2,250₩28m
Jun 25, 2026Eseueichihelseukeeotuja1hojohap (Controlling shareholder)Other (Capital reduction)-3,923,853 shares——

Annual financials

YearRevenueOperating income
2025₩21.2bn-₩8.3bn
2024₩5.7bn-₩16.1bn
2023₩4.4bn-₩13.4bn

Filing timeline